Drugs / JCXH-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06564194 | Sep 2024 → Jun 2026 overdue | respiratory syncytial virus infectious disease | Immorna Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-24 | Immorna Biotherapeutics, Inc. | Results 嘉晨西海RSV mRNA疫苗JCXH-108加速推进海外II期 immorna.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-24 | Immorna Biotherapeutics, Inc. | 嘉晨西海RSV mRNA疫苗JCXH-108加速推进海外II期 immorna.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564194 ↗ |
| Route | Intramuscular | “Each participant will receive a single dose of JCXH-108 administered intramuscularly (IM) on day 1.” NCT06564194 ↗ |